Studies on COVID-19-associated MAS patients showed that early use of IL-1 blocker anakinra reduces the need for intensive care and contributes to the improvement in laboratory and radiological findings [140,141,142]. This evidence concerns the gene IL1B and macrophage activation syndrome.